摩罗丹辅助瑞巴派特对Hp阴性慢性萎缩性胃炎患者胃组织病理评分及胃蛋白酶原水平的影响  

Effect of Moluodan Assisted Rebamipide on Gastric Histopathological Scores and Pepsinogen Levels in Patients with Hp Negative Chronic Atrophic Gastritis

作　　者：王崇文 王少华 WANG Chongwen;WANG Shaohua(Jiujiang Sixth People's Hospital(Jiujiang Lianxi District People's Hospital),Jiujiang Jiangxi 332005,China)

机构地区：[1]九江市第六人民医院(九江市濂溪区人民医院),江西九江332005

出　　处：《药品评价》2024年第9期1077-1080,共4页Drug Evaluation

摘　　要：目的为分析摩罗丹辅助瑞巴派特对幽门螺杆菌(Hp)阴性慢性萎缩性胃炎(CAG)患者胃组织病理评分及胃蛋白酶原水平的影响。方法本研究选取2021年1月至2023年1月九江市第六人民医院收治的Hp阴性CAG患者60例,按照随机数字表法分为两组,各30例。其中对照组采用瑞巴派特治疗,观察组在对照组基础上加用摩罗丹治疗。比较两组临床疗效、胃组织病理评分、血清中表皮生长因子(EGF)、前列腺素E2(PGE2)、胃蛋白酶原Ι(PGΙ)、胃蛋白酶原Ⅱ(PGⅡ)、胃蛋白酶原Ι/胃蛋白酶原Ⅱ(PGΙ/PGⅡ)、丙二醇(MDA)水平及不良反应。结果相较于对照组(73.33%),观察组治疗总有效率(93.00%)较高;治疗后,观察组慢性炎症评分(1.03±0.08)分、肠化生评分(2.45±0.35)分及胃萎缩评分(2.96±0.42)分均低于对照组的(1.65±0.12)分、(3.13±0.42)分、(3.64±0.23)分,观察组EGF水平(2.47±0.13)ng/mL及MDA水平(6.33±1.23)nmol/mL低于对照组的(3.33±0.24)ng/mL、(8.02±1.03)nmol/mL,PGE2水平(220.03±22.48)μg/L、PGΙ水平(125.19±14.14)μg/L及PGΙ/PGⅡ(6.21±1.03)%高于对照组的(197.24±21.03)μg/L、(102.68±15.98)μg/L、(5.50±0.98)%,差异有统计学意义(均P<0.05);两组PGⅡ比较差异无统计学意义(P>0.05)。两组均未出现严重不良反应。结论Hp阴性CAG患者采用摩罗丹辅助瑞巴派特治疗,效果显著,可有效减轻胃组织病理损伤,改善胃蛋白酶原及相关血清指标水平,且较为安全,具有临床借鉴价值。Objective Analyze the effect of moluodan assisted rebamipide on gastric histopathological scores and pepsinogen levels in patients with chronic atrophic gastritis(CAG)with negative helicobacter pylori(Hp).Methods 60 Hp negative CAG patients admitted to Jiujiang Sixth People's Hospital from January 2021 to January 2023 were divided into 2 groups with 30 each according to random number table method.The control group was treated with rebamipide,and the observation group was treated with moluodan on the basis of control group. Compare the clinical efficacy, gastric histopathological score, serum epidermal growth factor (EGF), prostaglandin E2 (PGE2), pepsinogen Ι (PG Ι), pepsinogenⅡ(PGⅡ), pepsinogen Ι/pepsinogenⅡ(PG Ι/ PGⅡ), propylene glycol (MDA) levels and adverse effects between two groups. Results The overall response rate (93.33%) was higher in the observation group compared to the control group (73.00%). The chronic inflammation score (1.03±0.08), intestinal metaplasia score (2.45±0.35) and gastric atrophy score (2.96±0.42) in the observation group were lower than the control group’s (1.65±0.12), (3.13±0.42) and (3.64±0.23);the EGF level (2.47±0.13) ng/mL and MDA level (6.33±1.23) nmol/mL were lower than the control group’s (3.33±0.24) ng/mL and (8.02±1.03) nmol/mL;PGE 2 level (220.03±22.48) μg/L, PG Ι (125.19±14.14) μg/L, and PG Ι/PGⅡ(6.21±1.03)% were higher than (197.24±21.03) μg/L, (102.68±15.98) μg/L, (5.50±0.98)% in the control group, with statistical difference (P<0.05). There was no statistical difference between the two groups of PGⅡ(P>0.05). Neither group had any serious adverse effects. Conclusion Patients with Hp negative CAG treated with moluodan assisted rebamipide, can effectively reduce the gastric histopathological damage, improve the level of pepsinogen and related serum indicators, which is relatively safe and has clinical reference value.

关 键 词：慢性萎缩性胃炎 HP阴性 摩罗丹 瑞巴派特 胃组织病理评分 胃蛋白酶原 

分 类 号：R73[医药卫生—肿瘤]